Two new Ebola vaccines to join DR Congo clinical trial

© WHO A participant in the eastern DR Congo receives a vaccine as part of a trial to tackle the Ebola Bundibugyo virus.
5 November 2026Health
Two new Ebola vaccine candidates will be added to a clinical trial in the Democratic Republic of the Congo (DRC) as the country continues to battle a deadly outbreak caused by the Bundibugyo species of the virus.
The announcement by the UN World Health Organization (WHO) follows the recommendation of its independent Technical Advisory Group on Candidate Vaccines Prioritization.
This will mark the first time that vaccines specifically designed for Bundibugyo virus will be evaluated during an outbreak of the disease.
“The fact that these vaccines are ready to enter clinical trials is a testament to the power of science and partnership,” said WHO Director-General Tedros Adhanom Ghebreyesus.
He stressed that while vaccines alone will not end the outbreak, “they could become a powerful new tool for bringing it under control”.
‘Hope’ as cases mount
The two vaccine candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and mRNA-1469, developed by the American pharmaceutical and biotech company Moderna.
WHO convened the expert group which this week recommended them for further clinical evaluation, based on available evidence.
The DRC has been battling a deadly outbreak of Ebola disease caused by the rare Bundibugyo virus species for nearly six months and it has become the largest in the country’s history. As of 1 November, there were more than 10,500 confirmed cases and 5,126 deaths.
WHO is supporting the Tumaini multi-vaccine trial, named after the Swahili word for “hope”. It was launched on 23 October in the eastern city of Bunia, capital of Ituri province, which remains the epicentre of the outbreak.
The Ervebo vaccine, used to treat the Zaire species of the Ebola virus, is already being tested to determine if it is effective against Bundibugyo species. The two new vaccine candidates will enter the trial following national approvals.
Tumaini is designed to test multiple vaccine candidates within a single trial, using a ring-vaccination approach that focuses on contacts of people with confirmed Ebola Bundibugyo.
WHO and partners pioneered the strategy during the West Africa Ebola outbreak a decade ago, where a trial in Guinea established the efficacy of the Ervebo vaccine.
Four vaccination rings have been set up and several more are being prepared, while research into other potential treatments is also moving forward.
Wendy’s Rejects Trian’s $1.4 Billion Takeover Offer
Company backs its own turnaround bid instead of being taken private by Nelson Peltz’s hedge fund
Wendy’s WEN 0.52%increase; green up pointing triangle has rejected an unsolicited $1.4 billion bid led by Nelson Peltz’s Trian Fund Management to buy the struggling burger chain, and adopted policies to protect the chain from further hostile takeover attempts.
The Ohio-based restaurant chain said Thursday that its board had unanimously rejected the investor group’s offer last week to buy out the company for $7.35 a share in cash. The company’s board said it is confident in new Chief Executive Bob Wright and his turnaround strategy, which is showing some early results. It also said the Trian proposal undervalues the company.
“Our confidence rests firmly in Bob Wright’s proven track record,” said Art Winkleblack, Wendy’s board chairman and a member of an independent committee that reviewed Trian’s proposal.
Wendy’s shares rose slightly.
Wendy’s, once the second-largest burger chain by U.S. sales, has been in a funk since last year. The company has had four CEOs since early 2024. In May, it appointed Wright, the chain’s former chief operating officer who previously served as CEO of sandwich chain Potbelly.
Peltz, a longtime Wendy’s shareholder who previously served as board chairman, said earlier this year that Trian had spoken to potential investors about strategic options for the burger chain. But in August, Trian said it was walking away from those efforts, which resulted in a decline in the company’s share price.
Trian and related parties hold a roughly 16% stake in Wendy’s. Peltz’s son, Bradley, sits on its board and operates Wendy’s restaurants.
Restaurant operator Flynn Group and the investment firms BlueFive Capital and Sixth Street Partners joined Trian in advancing its proposal last week. At that time, the Trian-led $1.4 billion proposal offered shareholders a 20% premium. Wendy’s had a valuation of around $1.46 billion as of Wednesday.
CVS bets on break-up to dodge political backlash against healthcare giants
Bipartisan campaign targeting consolidated ownership of pharmacies, insurers and prescription drug managers weighs on sector
Almost two decades to the day after CVS won the bidding for pharmacy benefit manager Caremark, the US healthcare giant said it would jettison its pharmacy business as mounting bipartisan pressure threatens its business model.
It said on Wednesday it would spin off about 9,000 pharmacies into a new public company, unwinding years of expansion that brought drugstores, health insurance and prescription management under one roof.
The move comes as public and political outrage over runaway healthcare costs and industry consolidation spelled the end for a strategy that turned the US pharmacy chain from a single drugstore in Lowell, Massachusetts, into one of the nation’s biggest healthcare conglomerates.
Shares in CVS fell 12.5 per cent on Wednesday as investors fretted over the potential distraction of an 18-month break-up and how the debt load would be shared between the two businesses.
Chief executive David Joyner defended the new strategy, telling analysts: “We are not doing anything out of a distressed decision.” Prior to Wednesday’s pullback, CVS’s shares had bounced back from a decade low in December 2024.
The model served investors well before the Covid-19 pandemic but it struggled in recent years as rising healthcare costs crimped margins and Amazon and Walmart began to compete for pharmacy business, both in prescriptions and household items such as detergent and toilet paper that aided profitability.
CVS’s troubles even drew the attention of activist hedge fund Glenview Capital, whose founder Larry Robbins served on the healthcare group’s board for two years until August.
Pressure from the Federal Trade Commission over drug pricing as well as Washington and US state capitals over combined ownership of pharmacies and PBMs presented an impasse for CVS and its rivals.
“PBMs are the bogeyman,” said Chris Meekins, a healthcare policy analyst at Raymond James. Companies have been relying on the courts to stop the laws, “but that is always a dangerous game” if they start to lose.
Democrat Ron Wyden, who in January will take over a US Senate panel overseeing the healthcare industry, said on Wednesday he would scrutinise conglomerates and “[end] the corporate chokehold on our nation’s healthcare system”.
Reforming the PBM system has been one of the few areas where there is cross-party agreement in Washington. Earlier this year, Republican senator Josh Hawley and Democrat Elizabeth Warren introduced a bill to ban large healthcare companies from owning pharmacies.
“All these huge companies gobbling up local pharmacies should be broken up,” Hawley said in a statement on Wednesday about the CVS spin-off.
At the state level, legislation to force CVS and others to break up their PBM businesses has already passed in Arkansas and Tennessee, though companies have challenged the laws in court. The CVS spin-off would appear to comply with these state regulations.
Speaking to CNBC, Joyner acknowledged how legislative pressure had weighed on the break-up decision. “What you see in the regulatory environment is clearly one of the things that we need to make sure we’re navigating, and we are positioning the company to be able to thrive regardless of how these companies are being expected to operate,” he said.
“CVS realised the insurance and PBM side of the company was more valuable,” prompting it to pursue the split, Meekins added.
In an interview with the FT last year, Arkansas Republican governor Sarah Huckabee Sanders said her state’s law was necessary because people sometimes struggled to get medicines from the big three pharmacy companies.
“When they get to own both sides of the negotiation, then the consumers are the ones who lose,” Sanders said. “PBMs have shown they care more about their bottom line and less about the people they are supposed to serve.”
CVS and other companies sued to stop the Arkansas law, which was halted by a federal district court judge last year. The litigation is ongoing. Groups have also sued to halt a similar law passed in Tennessee.
Investors said on Wednesday they were frustrated by the lack of details from CVS about the split. “The market might be just reacting negatively to the fact that this could be an 18-month overhang on the stock with lots of uncertainty leading up to the completion,” Daniel Barasa, a portfolio manager at Gabelli, said in an interview.
Other large healthcare groups were unlikely to follow CVS and break up their integrated businesses, he said. CVS was different because it has such a large retail pharmacy footprint.
“I don’t think this is a signal that you’ll see similar transactions from other big integrated players in the market,” said Barasa. “This is just [CVS] getting ahead of regulatory pressure.”
How Kalshi Is Spinning Up New Markets for Big Investors
The Takeaway
- Kalshi develops bespoke prediction contracts for institutional investors.
- Grand Teton Systems requested NCAA settlement payout hedging contracts.
- Prediction markets aim to attract big traders for financial risk hedging.
Kalshi wants to become a major challenger to traditional financial markets by encouraging big funds and companies to use prediction markets to protect against losses. Behind the scenes, it’s developing new contracts to win those big investors over.
That includes wagers aimed at niche corners of finance like the market for legal claims, where investors buy up claims at a discount betting they’ll be worth more once settlements are resolved. Last month, at a big investor’s request, Kalshi added new prediction contracts on the timing and size of payouts in the $2.8 billion settlement between college athletes and the National Collegiate Athletic Association.
The idea came from investment firm Grand Teton Systems, which has bought about $400 million worth of claims from athletes. Louis d’Origny, co-founder of GTS, said he reached out to Kalshi because he wanted a way for claim holders to hedge the risk that the payments might come in smaller or later than expected.
Under a court-approved settlement from last year, the NCAA is due to distribute back pay to college athletes who said they were illegally barred from sharing in revenue it made from broadcasting their games or using their name, image and likeness. But female athletes have challenged the settlement, saying they aren’t getting their fair share compared to male athletes, and that has put payouts on hold.
The size and timing of individual payouts remains a question, which could also mean different tax implications for claimants based on when the back pay hits. Though Kalshi offers yes-no bets on everything from election outcomes and sports to “Dancing With the Stars” weekly winners—and even the outcome of some high-profile court decisions like Trump’s BBC lawsuit and Amazon’s antitrust case—it didn’t have any contracts to make wagers on how the NCAA settlement will play out.
D’Origny said he suggested new contracts tied to some of the yet-to-be-resolved details. About 72 hours later, two new contracts went live on Kalshi—one allowing customers to bet on whether women will get a bigger share of the back pay and a second on when payments will begin. “Whats exciting is that this is a genuine hedging opportunity for real world risk,” d’Origny said.
Kalshi and rival Polymarket both see a major growth opportunity in courting big traders to their platforms, arguing that they can use its contracts much as they would traditional futures contracts to hedge against things like interest rate changes or fluctuations in prices of commodities such as oil. Kalshi, which announced last week it had raised $1 billion at a $40 billion valuation, says that as of September it worked with 500 institutional customers making up around 25% of its trading volume.
Both businesses are still dominated by sports betting, which accounts for about 90% of trading volume on each platform, and having more financial customers could also help with the prediction markets’ regulatory standing. Sports predictions in particular have drawn the ire of lawmakers and embroiled Kalshi, Polymarket and other competitors in lawsuits from dozens of states over accusations that the firms are running illegal gambling operations.
Prediction markets offer more types of bets than traditional futures markets, creating the opportunity for entirely new forms of hedges. But high-profile examples of businesses using prediction market contracts have so far mostly involved hedgers using existing contracts.
They’ve included a bar in New York hedging a free drinks promotion during the National Basketball Association finals and a Los Angeles ice cream shop betting on colder weather to insure against lower sales. And while Kalshi has announced it’s worked with investors like Ark Invest to develop new contracts, the examples it has cited include bets on topics with broad interest, like non-farm payroll numbers.
That makes GTS’ request an interesting test case for Kalshi’s efforts to grow its institutional business. Large class-action settlements or major bankruptcies often attract investment firms because they involve thousands of claimants who may be enticed by an up-front payment payment, especially in complex cases that could take years to shake out.
Notably, GTS became the largest buyer of claims in the bankruptcy of Sam Bankman-Fried’s FTX. D’Origny, himself an FTX creditor, spotted an opportunity to buy bankruptcy claims at a discount from others who wanted a quick payout. GTS launched a website called FTXCreditor to solicit claims and eventually took ownership of almost 5,000 FTX claims.
The long-running dispute between college athletes and the NCAA, which covers athletes who competed as far back as 2016, is proving to be another opportunity for GTS. The firm has been running a website encouraging athletes to sell their settlement claims to receive immediate cash. The website notes that almost 6,000 athletes have opted in so far.
The contracts Kalshi created for d’Origny so far have drawn meager volume, and GTS itself hasn’t traded them yet because it hasn’t seen a favorable position to take. “We would hedge more exposure if we saw interesting odds,” d’Origny said.
But d’Origny said the markets offer other benefits, because athletes who sell a claim to GTS could use the markets to place bets that could boost their total payoff. “This actually competes with our product offering,” he said. “We take on the risk entirely for athletes. Here they have a new avenue.”
The contracts could also offer free marketing for GTS’ efforts to buy up claims. “People talking about the settlement might encourage some to sell,” he said.
Meta acquires AI coding startup Conductor
Meta has acquired Conductor, an AI coding startup that allows users to spin up software projects by deploying multiple agents into parallel workspaces.
The news was originally reported by Axios, and Conductor shared news of its acquisition on its blog.
“I have big news: Conductor is joining Meta,” wrote the startup’s founder and CEO, Charlie Holtz, on Wednesday. “We have some big, crazy plans for the next interface,” he added, teasing that the company would have “something new” for customers to use by “early next year.”
On X, Holtz also noted that he was looking forward to working with Alexandr Wang, Meta’s chief AI officer, and Nat Friedman, head of product at the company’s Superintelligence Labs. “They’ve been on an absolute tear, and I’m convinced MSL has the highest talent density of all the labs,” he added.
Meta confirmed the acquisition to TechCrunch but wouldn’t comment further or provide additional details about the deal.
Conductor, founded in 2024, only launched its core product just last summer. The company’s agentic teams, which can be deployed in the cloud, locally, or via a user’s phone, are designed to help software engineers work on separate, compartmentalized parts of a project in concert. The agents that the platform deploys aren’t developed in-house but come from major labs like Anthropic and OpenAI.
Holtz said that, until early next year, Conductor’s core features would continue to work as they previously have. The exception is Conductor’s cloud service, which will shut down on November 20, after which the company will begin deleting user cloud data.
Meta, which previously lagged behind in AI services, has spent the last several months trying to catch up. In August, the company launched Muse Code, its own coding agent. Meanwhile, the company’s recently launched Muse agents are seeing significant adoption, with the company recently reporting that the service had surpassed 10 million users. The company has also made a number of AI-related acquisitions over the past year, including Moltbook, the viral agent platform that made headlines.
>>> Up
* Administer Raised to Accumulate at Inderes; PT 2.60 euros
* Afya Raised to Equal-Weight at Morgan Stanley; PT $12.60
* Bouvet Raised to Buy at SB1 Markets; PT 60 kroner
* Enea Raised to Buy at Wood & Company; PT 28.10 zloty
* Galp Raised to Add at AlphaValue/Baader
* Morgan Sindall Raised to Buy at Peel Hunt; PT 5,700 pence (+)
* PGE Raised to Buy at Wood & Company; PT 18.50 zloty
* Volaris ADRs Raised to Buy at Grupo Santander; PT $9.40
* Volaris ADRs Raised to Buy at Grupo Santander; PT $9.40
* Wallenius Wilhelmsen Raised to Buy at SEB Equities
* Wallenius Wilhelmsen Raised to Buy at SB1 Markets; PT 195 kroner (+)
* Wereldhave Raised to Buy at KBC Securities; PT 21 euros (+)
>>> Down
>>> Down
* Flutter PT Cut to $160 from $180 at Jefferies
* HubSpot Cut to Sector Weight at KeyBanc
* HubSpot Cut to Sector Weight at KeyBanc
* HubSpot Cut to Underweight at Cantor; PT $170
* Michelin Cut to Underweight at Barclays; PT 30 euros
* MNTN Cut to Market Perform at Citizens
* Nyab Cut to Accumulate at Inderes; PT 9.50 kronor
* Sampo Cut to Accumulate at Inderes; PT 10.50 euros
* Schott Pharma Cut to Sector Perform at RBC; PT 25 euros
* Siltronic Cut to Underperform at BofA; PT 55 euros (+)
* Swisscom 3Q Net Revenue Beats Estimates
* Technogym Raised to Buy at Citi; PT 17 euros
>>> Initiation
* SpaceX Rated New Buy at China Renaissance; PT $194.20
>>> Initiation
* SpaceX Rated New Buy at China Renaissance; PT $194.20
* Vicore Pharma Rated New Buy at Arctic Securities; PT 36 kronor
* Vicore Pharma ADRs Rated New Buy at Chardan Capital Markets
>>> Call
* Michelin Faces Further Reset, Barclays Cuts to Underweight
>>> Call
* Michelin Faces Further Reset, Barclays Cuts to Underweight
* Schott Pharma Cut to Sector Perform at RBC After Rally in Shares (+)
* Siltronic Falls; Cut to Underperform at BofA on Cost Headwinds
* Tecan Jumps on Raised Oulook, Possible AI Boost: Street Wrap (+)
* Technogym Moving Past Organic Growth Trough, Upgraded at Citi
Palo Alto Networks in Talks to Pay $500 Million for AI Security Startup
The Takeaway
- Palo Alto Networks eyes $500 million acquisition of Clutch Security.
- Clutch Security tracks passwords and authentication codes for AI agents.
- Palo Alto’s fifth potential acquisition this year would target growing AI security risks.
Palo Alto Networks is in talks to buy three-year-old Israeli security startup Clutch Security for around $500 million, according to people familiar with the matter.
If finalized, the acquisition would be the fifth Palo Alto Networks has announced this year, as CEO Nikesh Arora seeks to bolster the company’s products that counter new AI threats. Clutch develops software that helps companies track passwords and authentication codes used by AI agents.
Discussions are ongoing and may not lead to a deal. A Palo Alto Networks spokesperson said the company doesn’t comment about “rumors or speculation.” A spokesperson for Clutch Security didn’t immediately respond to a request for comment.
The startup has raised more than $20 million from investors including Lightspeed Venture Partners and SignalFire. Its current valuation couldn’t be learned.
The acquisition could further deepen Palo Alto Networks’ offerings in identity security—the software that helps businesses manage logins and other permissions to make sure their users only access the data they’re supposed to. Earlier this year, Palo Alto, which has a market cap of $287 billion, completed its $25 billion acquisition for CyberArk, the market leader in identity security. While CyberArk had historically focused on managing human users’ logins, Clutch tries to corral AI agents’ use of passwords and data.
The cybersecurity sector has found its services in high demand from rising AI-related threats, as new AI models have shown they can find serious flaws in widely used software that attackers can exploit. Meanwhile, a string of high-profile incidents involving AI agents that have breached other companies’ systems has highlighted the need for security that labels, tracks and controls customers’ AI agents.
These risks have spurred a string of acquisitions for startups that provide safeguards against AI agent blunders. Last month, HR and finance company Workday acquired startup C1.ai to manage AI agent identities alongside human identities. In August, identity security company Okta acquired Permiso Security and rival Sailpoint acquired Entro Security in June, both due to the targets’ specialization in managing AI agent identities.
China blocks SoftBank’s $5.4bn takeover of ABB’s robotics division
Swiss-Swedish company’s unit is focused on Chinese market and has mega-factory in Pudong
China has told SoftBank it will not allow the $5.4bn acquisition of ABB’s robotics division to go ahead in a shock move that threatens to throw Masayoshi Son’s ambitions in physical AI into disarray.
SoftBank was recently informed that the deal would be blocked by China’s National Development and Reform Commission, the powerful state planner tasked with safeguarding supply chain security and stability, according to multiple people familiar with the matter.
China is the biggest market for ABB’s robotics unit, with more than 90 per cent of its robots for Chinese customers manufactured locally. The Swiss-Swedish company employs about 12,700 people in China.
Until last week, people close to SoftBank and those briefed on the NDRC’s process in China had expected the deal to be approved despite it being subject to a foreign investment security review.
ABB confirmed in a statement on Thursday it has been informed by SoftBank that Chinese regulators had “prohibited the acquisition of the ABB Robotics business in China”.
SoftBank is now trying to determine what went wrong and whether it could try to seek approval again. The ABB division’s operations in China were a significant attraction for the deal, say people close to the Japanese group.
The NDRC review had included detailed scrutiny of ABB’s Chinese supply chains and a demand to retain some of the robotics unit’s manufacturing capabilities in China, according to people familiar with the matter.
The ABB unit had been a key part of SoftBank founder Masayoshi Son’s bet on physical AI © Fred Mery/Bloomberg
SoftBank agreed last October to buy ABB’s robotics division as part of the Japanese group’s push into a sector it believes will be tied to the rise of AI.
The deal cleared China’s competition review in February. It then became subject to a foreign investment security review that highlighted Beijing’s concern over the transfer of assets developed in China to a Japanese company at a time of heightened tensions with Tokyo and strategic competition with Washington.
The NDRC had been concerned about robotics data being transferred overseas, where it could be used to train AI models, including those developed by OpenAI, in which SoftBank is a major investor, said people familiar with the matter.
ABB set up a joint venture with a Chinese partner in 1992 and its China operations, particularly its robotics business, have long benefited from government support. Shanghai’s government also helped ABB build its $150mn robotics mega-factory in Pudong, which began operating in 2022.
According to people briefed on their thinking, regulators had also examined keeping intellectual property relating to some of ABB’s robotics business in China, potentially requiring parts of the business to be spun off to Chinese owners for the deal to proceed.
However, those close to SoftBank say there was uncertainty in Japan about which conditions were being formally requested in the days leading up the decision to block the deal.
SoftBank declined to comment.
For SoftBank, ABB’s robotics business has been a key part of founder Son’s bet on physical AI and was intended to form the basis of his plans in the sector along with AI and robotics company Roze in the US.
Son is also in talks to buy Allied Universal, the world’s largest private security group and owner of the UK’s G4S, with a view to using robotics and AI to increase productivity.
SoftBank shares have fallen 38 per cent in the past month and by 28 per cent over the past year amid concerns about AI demand and, in particular, OpenAI’s decision to push its IPO into next year.
That delay has also put pressure on SoftBank’s looming listing of its US data centre developer SB Energy, which is targeting a $50bn valuation.
The NDRC did not immediately reply to a request for comment.